John R. Moore - Sep 6, 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
General Counsel
Signature
/s/ John R. Moore
Stock symbol
EWTX
Transactions as of
Sep 6, 2022
Transactions value $
-$42,469
Form type
4
Date filed
9/8/2022, 04:16 PM
Previous filing
Aug 10, 2022
Next filing
Oct 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $9.13K +4.73K +157.67% $1.93 7.73K Sep 6, 2022 Direct
transaction EWTX Common Stock Sale -$25.8K -2.38K -30.78% $10.83 5.35K Sep 6, 2022 Direct F1, F2
transaction EWTX Common Stock Sale -$25.8K -2.35K -43.94% $10.99 3K Sep 6, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -4.73K -3.57% $0.00 128K Sep 6, 2022 Common Stock 4.73K $1.93 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.
F2 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.93 to $10.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $10.93 to $11.08, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 1/48th of the shares subject to the option vest monthly beginning on January 16, 2021, subject to Reporting Person continuing as a service provider through each vest date.